Pacaud, Lida
Medical College of Wisconsin · Josep Carreras Leukaemia Research Institute · Hospital Clínic de Barcelona · Instituto de Investigación Biomédica de Salamanca · Clinica Universidad de Navarra · Centro de Investigación Biomédica en Red de Cáncer · Centro de Investigación Médica Aplicada · Legend Biotech (United States) · University College London · Universitat de Barcelona
6 papers on CoChatORCID 0000-0002-7803-2366
Most cited papers
- Verified
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 4,112
- Verified
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsCAR-T cell therapy research
Cited by 827
- Verified
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 663
- Verified
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Cohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N. W. C. J., Arnulf, B., Mateos, M.-V., Lendvai, N., Jackson, C. C., De Braganca, K. C., et al. (2022) · Blood Cancer Journal
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 308
- Verified
Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
Van De Donk, N. W., Agha, M., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W. W. H., Schecter, J. M., De Braganca, K. C., Jackson, C. C., et al. (2022) · Blood
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 25
- Verified
P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database
Dhakal, B., Einsele, H., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., et al. (2022) · Clinical Lymphoma Myeloma and Leukemia
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 3
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free